 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
|
||
 |
|
||||||
 |
|
||||||
 |
Home | Intranet | Site Map | Search |  |
|
||||
 |
|
||||||
|
Massachusetts Institute of Technology, 1995, Ph.D.
The long term research goals of my laboratory are to understand the molecular and cellular basis of prostate cancer metastasis in order to develop new methods to treat this disease. We are modeling prostate cancer metastasis in animals with the aim of understanding better the fundamental biology of this disease. Utilizing bioluminescence imaging technology to monitor the dissemination and growth of tumor cells we have developed models of metastatic colonization of bone that reflects pathologic features of human prostate cancer metastasis. Specific efforts are focused on understanding the role of endothelin-1, a target of current clinical interest, which may be involved in mediating interactions between cancer cells and metastatic organ environments. We are also interested in other cellular and molecular mechanisms that may contribute to prostate cancer metastasis, including the role that fusion between cancer and normal cells might play in this process and events that may lead to invasive phenotypes in metastatic prostate cancer cells including the loss of dystroglycan expression. Finally, we are employing our animal models to test novel therapeutic approaches to prostate cancer metastasis.
1. Svensson, R.U., Barnes, M.J. Rokhlin, O., Cohen, M.B. and Henry, M.D. Chemotherapeutic Agents Upregulate the CMV Promoter via p38 MAPK: Implications for Bioluminescence Imaging of Tumor Response to Therapy. Cancer Research, In press, 2007. 2. Drake, J.M., Gabriel, C L. and Henry, M.D. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin. Exp. Metastasis, 22:674-684, 2005.
|
|||||||||||||||
Associate Professor